KR101276513B1 - 인슐린-유사 성장 인자 ｉ 수용체에 대한 항체 및 그의 용도 - Google Patents

인슐린-유사 성장 인자 ｉ 수용체에 대한 항체 및 그의 용도 Download PDF

Info

Publication number
KR101276513B1
KR101276513B1 KR1020087024802A KR20087024802A KR101276513B1 KR 101276513 B1 KR101276513 B1 KR 101276513B1 KR 1020087024802 A KR1020087024802 A KR 1020087024802A KR 20087024802 A KR20087024802 A KR 20087024802A KR 101276513 B1 KR101276513 B1 KR 101276513B1
Authority
KR
South Korea
Prior art keywords
igf
antibody
ser
cells
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020087024802A
Other languages
English (en)
Korean (ko)
Other versions
KR20080113233A (ko
Inventor
질케 한젠
클라우스-페터 퀸켈레
디트마르 로이슈
랄프 슈마허
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101276513(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20080113233A publication Critical patent/KR20080113233A/ko
Application granted granted Critical
Publication of KR101276513B1 publication Critical patent/KR101276513B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020087024802A 2006-04-11 2007-04-10 인슐린-유사 성장 인자 ｉ 수용체에 대한 항체 및 그의 용도 Active KR101276513B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06007571 2006-04-11
EP06007571.0 2006-04-11
PCT/EP2007/003165 WO2007115814A2 (en) 2006-04-11 2007-04-10 Antibodies against insulin-like growth factor i receptor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020127002545A Division KR20120028396A (ko) 2006-04-11 2007-04-10 인슐린-유사 성장 인자 ｉ 수용체에 대한 항체 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20080113233A KR20080113233A (ko) 2008-12-29
KR101276513B1 true KR101276513B1 (ko) 2013-06-21

Family

ID=36940705

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087024802A Active KR101276513B1 (ko) 2006-04-11 2007-04-10 인슐린-유사 성장 인자 ｉ 수용체에 대한 항체 및 그의 용도
KR1020127002545A Ceased KR20120028396A (ko) 2006-04-11 2007-04-10 인슐린-유사 성장 인자 ｉ 수용체에 대한 항체 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127002545A Ceased KR20120028396A (ko) 2006-04-11 2007-04-10 인슐린-유사 성장 인자 ｉ 수용체에 대한 항체 및 그의 용도

Country Status (20)

Country Link
US (1) US20080014203A1 (enExample)
EP (2) EP2007810B1 (enExample)
JP (1) JP4718634B2 (enExample)
KR (2) KR101276513B1 (enExample)
CN (1) CN101421305B (enExample)
AR (1) AR060592A1 (enExample)
AU (1) AU2007236199B2 (enExample)
BR (1) BRPI0710185B8 (enExample)
CA (2) CA2647181C (enExample)
CR (1) CR10301A (enExample)
EC (1) ECSP088816A (enExample)
ES (1) ES2403075T3 (enExample)
IL (1) IL194397A (enExample)
MX (1) MX2008012950A (enExample)
NO (1) NO20084082L (enExample)
NZ (1) NZ571414A (enExample)
RU (1) RU2541765C2 (enExample)
UA (1) UA95284C2 (enExample)
WO (1) WO2007115814A2 (enExample)
ZA (1) ZA200808597B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
CA2709029A1 (en) 2007-12-21 2009-07-02 Bianca Eser Stability testing of antibodies
CN103396487A (zh) 2008-12-12 2013-11-20 贝林格尔.英格海姆国际有限公司 抗igf抗体
WO2010112194A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
KR20120031083A (ko) 2009-07-24 2012-03-29 에프. 호프만-라 로슈 아게 교반기 시스템
WO2011044336A2 (en) * 2009-10-07 2011-04-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (igf) system
HUE033758T2 (en) 2009-10-26 2017-12-28 Hoffmann La Roche A method for producing glycosylated immunoglobulin
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
JP5947802B2 (ja) 2010-11-05 2016-07-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ミックスモードクロマトグラフィーによる抗体捕捉の最適化方法
ES2667864T3 (es) 2011-06-22 2018-05-14 F. Hoffmann-La Roche Ag Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I
RU2502798C2 (ru) * 2012-02-22 2013-12-27 Общество с ограниченной ответственностью "Фармако Биотех" КЛЕТОЧНАЯ ЛИНИЯ huFSHIK, СЕКРЕТИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ЧЕЛОВЕЧЕСКИЙ ФСГ
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
EP2914629A1 (en) 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
RU2015129640A (ru) 2012-12-21 2017-01-26 Ф.Хоффманн-Ля Рош Аг Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2021119234A1 (en) * 2019-12-10 2021-06-17 Horizon Pharma Ireland Ltd. Glycosylated antibodies against insulin-like growth factor i receptor and uses thereof
JP2023545520A (ja) 2020-10-14 2023-10-30 ビリジアン セラピューティクス， インコーポレイテッド 甲状腺眼疾患を治療するための組成物及び方法
WO2023019171A1 (en) 2021-08-10 2023-02-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005635A2 (en) * 2003-07-10 2005-01-20 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5610297A (en) * 1991-12-27 1997-03-11 Georgia Tech Research Corp. Peptides ketoamides
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
CA2369292C (en) * 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
EP2316922B1 (en) * 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
JP4473257B2 (ja) * 2003-04-02 2010-06-02 エフ．ホフマン−ラ ロシュ アーゲー インスリン様成長因子ｉ受容体に対する抗体及びその使用
EP1666501A4 (en) * 2003-08-11 2008-12-24 Chugai Pharmaceutical Co Ltd ANTI-HM1.24 ANTIBODIES WITH MODIFIED SUGAR CHAIN
WO2005034994A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 固形腫瘍治療剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005635A2 (en) * 2003-07-10 2005-01-20 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Biological Chemistry vol.278, pp.3466-3473 *
Journal of Biological Chemistry vol.278, pp.3466-3473*

Also Published As

Publication number Publication date
CN101421305A (zh) 2009-04-29
WO2007115814A3 (en) 2008-01-10
EP2007810A2 (en) 2008-12-31
ES2403075T3 (es) 2013-05-13
AU2007236199B2 (en) 2013-07-25
WO2007115814A2 (en) 2007-10-18
AR060592A1 (es) 2008-07-02
EP2007810B1 (en) 2013-02-13
EP2363417A1 (en) 2011-09-07
BRPI0710185B1 (pt) 2020-01-14
NO20084082L (no) 2008-11-06
CA2647181C (en) 2020-08-11
UA95284C2 (ru) 2011-07-25
AU2007236199A1 (en) 2007-10-18
CA2647181A1 (en) 2007-10-18
ECSP088816A (es) 2008-11-27
JP4718634B2 (ja) 2011-07-06
KR20120028396A (ko) 2012-03-22
CA3081707A1 (en) 2007-10-18
BRPI0710185A2 (pt) 2011-08-09
CR10301A (es) 2008-10-29
ZA200808597B (en) 2009-11-25
JP2009533367A (ja) 2009-09-17
NZ571414A (en) 2011-12-22
IL194397A (en) 2014-04-30
IL194397A0 (en) 2011-08-01
RU2541765C2 (ru) 2015-02-20
KR20080113233A (ko) 2008-12-29
US20080014203A1 (en) 2008-01-17
BRPI0710185B8 (pt) 2021-05-25
RU2008144290A (ru) 2010-05-20
CN101421305B (zh) 2013-05-15
MX2008012950A (es) 2008-10-15
BRPI0710185A8 (pt) 2019-01-22

Similar Documents

Publication Publication Date Title
KR101276513B1 (ko) 인슐린-유사 성장 인자 ｉ 수용체에 대한 항체 및 그의 용도
KR101256257B1 (ko) 글리코실화된 항체
EP1959014B1 (en) Antibodies against insulin-like growth factor I receptor and uses thereof
US20080226635A1 (en) Antibodies against insulin-like growth factor I receptor and uses thereof
KR20100097737A (ko) Ｃｃｒ５에 대한 어푸코실화된 항체 및 이의 용도
HK1126796A (en) Antibodies against insulin-like growth factor i receptor and uses thereof
HK1134829A (en) Antibodies against insulin-like growth factor i receptor and uses thereof

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20081010

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
AMND Amendment
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101227

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110929

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20101227

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20111230

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20110929

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20130426

Appeal identifier: 2011101010742

Request date: 20111230

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20120130

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20111230

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20111230

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20110317

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20081013

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20130426

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20120131

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20130612

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20130612

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20160330

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20170330

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20170330

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20180329

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20190327

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20200324

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20210329

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20230327

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20240527

Start annual number: 12

End annual number: 12